PubRank

Linda Vahdat

Author PubWeight™ 26.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007 2.20
2 Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010 2.03
3 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007 1.99
4 Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006 1.69
5 Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2008 1.69
6 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007 1.60
7 Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009 1.54
8 Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014 1.32
9 Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003 1.13
10 Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006 1.05
11 The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma. Breast J 2007 1.05
12 Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008 1.04
13 Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 2009 1.00
14 Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis. Circ Res 2009 0.98
15 Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health 2012 0.87
16 Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat 2007 0.86
17 Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast 2011 0.85
18 Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 2005 0.83
19 A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 2003 0.83
20 Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting. Clin Breast Cancer 2008 0.79
21 Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer 2012 0.78
22 Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2015 0.77
23 Dermatological toxicity of ixabepilone. Anticancer Res 2006 0.75